Variation in nectar volume and sugar content in male flowers of Musa cultivars grown in Rwanda and their non-effect on the numbers of visiting key diurnal insect vectors of banana Xanthomonas wilt

Insects are a major mode of banana Xanthomonas wilt (XW) spread. High insect activity has been blamed for the high XW incidence in ‘Kayinja’ (ABB-genome) dominated banana landscapes across east and central Africa. ‘Kayinja’ male bud nectar composition reportedly contributes to high insect activity. The variation in nectar composition with agro-ecological zones and banana cultivars and its influence on the number of visiting insects in Rwanda were assessed. Three male buds were collected per cultivar for nectar extraction and analysis using a high performance liquid chromatography. Nectar volume and sugar concentrations varied (P<0.001) across 27 banana cultivars, annual seasons and agro-ecological zone. The highest nectar volume was recorded among the East African highland cooking cultivars (AAA-genome) in the high altitude site and the short-heavy rainy season. Nectar contained three sugars: glucose, fructose and sucrose, though hexose (glucose and fructose) was dominant. The three sugars varied significantly (P<0.001) within each cultivar. The total nectar-sugar concentration ranged from 2.3–32%, with the highest among dessert cultivars ‘Kamaramasenge’ (AAB-genome) and ‘Gisukari’ (AAA-genome). No strong correlation occurred between insect population and total nectar sugar concentration or nectar volume. Insect populations were rather influenced by the weather conditions, the long rainy season characterized by moderate well distributed rainfall recording the highest insect populations as compared to the short rainy season (with heavy rainfall) and the dry seasons

Spatial and temporal distribution of insect vectors of Xanthomonas campestris pv. musacearum and their activity across banana cultivars grown in Rwanda.

Insect vectors of Xanthomonas campestris pv musacearum (Xcm) have played a major role in long distance and plant to plant transmission of Xanthomonas wilt of banana (XW). The prevalence of insects has been reported to vary in space and time. Some banana cultivars have also been reported to attract more insect vectors of Xcm than others. The present study was conducted to determine the spatial and temporal distribution of insect vectors of Xcm and assess their activity across banana cultivars grown in Rwanda. The study was carried out in four banana growing areas of Rwanda selected on the basis of their altitude (i.e.Low, Medium and High). The Kivu Lake Border region was selected as a fourth site due to the high prevalence of XW. Insects were sampled in the four annual seasons (short dry, short rainy, long dry and long rainy) and at different times of the day. During sampling of insects, the incidence of XW-male bud infection was also recorded. Collected insects were immediately sorted into taxonomic groups and conserved in vials containing 70% ethanol for further identification to genus and species level. Five insect specimens in each taxon were put aside for the isolation of Xcm on their external body parts. There was a high prevalence of fruit flies, honey bees and other flies (in other families than Drosophilidae and Tephritidae) compared with wasps, ants and beetles. More insects were recorded in the low altitude area and during the long rainy season. These findings correlated with the observed high incidence of XW in the wet seasons. Incidence of floral infections was higher in the low altitudes declining with the increase in altitude, correlating with the decline in insect activity as altitude increased. The activity of insects on banana male buds varied among banana cultivars, with more activity on beer (AAA-East African Highland (EAH) and ABB types) and dessert banana cultivars compared with cooking or mixed use cultivars. Among the cooking types only ‘Injagi’ and its clone sets ‘Barabeshya’ and ‘Incakara’ attracted large insect populations. Banana cultivars ‘Nkazikamwe’ (cooking AAA-EAH), ‘Impura’ (beer AAAEAH) and ‘Ikinyangurube’ (dessert AAA) possessed persistent male bracts and neuter flowers and were less attractive to flower visitors. These cultivars could be promoted in areas prone to insect vector infections. Timely and proper de-budding should be emphasized with special attention during the rainy seasons and for banana cultivars with non-persistent male buds

Systematic Review and Meta-analysis of SurgicalTreatment of Non-Zenker?s Oesophageal Diverticula

Background Oesophageal diverticula are rare outpouchings of the oesophagus which may be classified anatomically as pharyngeal (Zenker’s), mid-oesophageal and epiphrenic. While surgery is indicated for symptomatic patients, no consensus exists regarding the optimum technique for non-Zenker’s oesophageal diverticula. The aim of this study was to determine the outcome of surgery in patients with non-Zenker’s oesophageal diverticula. Methods PubMed, MEDLINE and the Cochrane Library (January 1990 to January 2016) were searched for studies which reported outcomes of surgery in patients with non-Zenker’s oesophageal diverticula. Primary outcome measure was the rate of staple line leakage. Results Twenty-five observational studies involving 511 patients (259 male, median age 62 years) with mid-oesophageal (n = 53) and epiphrenic oesophageal (n = 458) diverticula who had undergone surgery [thoracotomy (n = 252), laparoscopy (n = 204), thoracoscopy (n = 42), laparotomy (n = 5), combined laparoscopy and thoracoscopy (n = 8)] were analysed. Myotomy was performed in 437 patients (85.5%), and anti-reflux procedures were performed in 342 patients (69.5%). Overall pooled staple line leak rates were reported in 13.3% [95% c.i. (11.0–15.7), p < 0.001] and were less common after myotomy (12.4%) compared with no myotomy (26.1%, p = 0.002). Conclusions No consensus exists regarding the surgical treatment of non-Zenker’s oesophageal diverticula, but staple line leakage is common and is reduced significantly by myotomy

Non-chemical signalling between mitochondria

A wide variety of studies have reported some form of non-chemical or non-aqueous communication between physically isolated organisms, eliciting changes in cellular proliferation, morphology, and/or metabolism. The sources and mechanisms of such signalling pathways are still unknown, but have been postulated to involve vibration, volatile transmission, or light through the phenomenon of ultraweak photon emission. Here, we report non-chemical communication between isolated mitochondria from MCF7 (cancer) and MCF10A (non-cancer) cell lines. We found that mitochondria in one cuvette stressed by an electron transport chain inhibitor, antimycin, alters the respiration of mitochondria in an adjacent, but chemically and physically separate cuvette, significantly decreasing the rate of oxygen consumption compared to a control (p = &lt;0.0001 in MCF7 and MCF10A mitochondria). Moreover, the changes in O2-consumption were dependent on the origin of mitochondria (cancer vs. non-cancer) as well as the presence of “ambient” light. Our results support the existence of non-chemical signalling between isolated mitochondria. The experimental design suggests that the non-chemical communication is light-based, although further work is needed to fully elucidate its nature

Efficacy and safety of oral methazolamide in patients with type 2 diabetes: A 24-week, placebo-controlled, double-blind study

OBJECTIVE To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes. RESEARCH DESIGN AND METHODS This double-blind, placebo-controlled study randomized 76 patients to oral methazolamide (40 mg b.i.d.) or placebo for 24 weeks. The primary efficacy end point for methazolamide treatment was a placebo-corrected reduction in HbA1c from baseline after 24 weeks (ΔHbA1c). RESULTS Mean ± SD baseline HbA1c was 7.1 ± 0.7% (54 ± 5 mmol/mol; n = 37) and 7.4 ± 0.6% (57 ± 5 mmol/mol; n = 39) in the methazolamide and placebo groups, respectively. Methazolamide treatment was associated with a ΔHbA1c of –0.39% (95% CI –0.82, 0.04; P < 0.05) (–4.3 mmol/mol [–9.0, 0.4]), an increase in the proportion of patients achieving HbA1c ≤6.5% (48 mmol/mol) from 8 to 33%, a rapid reduction in alanine aminotransferase (∼10 units/L), and weight loss (2%) in metformin-cotreated patients. CONCLUSIONS Methazolamide is the archetype for a new intervention in type 2 diabetes with clinical benefits beyond glucose control

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study

INTRODUCTION: Many patients with severe asthma continue to experience symptoms and exacerbations despite treatment with standard-of-care therapy. In the phase 3 NAVIGATOR study, tezepelumab significantly reduced exacerbations over 52 weeks compared with placebo in patients with severe, uncontrolled asthma. This analysis assessed the efficacy of tezepelumab in reducing asthma exacerbations in various clinically relevant subgroups of patients in NAVIGATOR. METHODS: NAVIGATOR was a phase 3, multicentre, randomized, double-blind, placebo-controlled study. Participants (12-80 years old) with severe, uncontrolled asthma were randomized 1:1 to receive tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. Pre-specified and post hoc analyses were performed to evaluate the annualized asthma exacerbation rate (AAER) over 52 weeks in clinically relevant subgroups of patients defined by baseline patient characteristics, medical history, exacerbation triggers, medication eligibility and medication use before and during the study. RESULTS: Tezepelumab reduced the AAER over 52 weeks compared with placebo across a wide range of patient subgroups assessed. Reductions in exacerbations were similar across subgroups defined by baseline patient characteristics, ranging from 48% (95% confidence interval [CI]: 21, 65) to 60% (95% CI: 44, 71) in subgroups analysed by sex, smoking history and body mass index. Among the asthma-related comorbidity subgroups investigated, patients with aspirin or NSAID sensitivity had the greatest reductions in AAER with tezepelumab compared with placebo (83%; 95% CI: 66, 91). In patients eligible to receive dupilumab, tezepelumab reduced exacerbations compared with placebo by 64% (95% CI: 54, 71). Reductions in the AAER with tezepelumab compared with placebo were also observed irrespective of exacerbation trigger category and the number of asthma controller medications patients were receiving at baseline. CONCLUSION: These findings further support the benefits of tezepelumab in patients with severe, uncontrolled asthma and can help to inform healthcare providers\u27 treatment decisions

Taking the Measure of the Universe: Precision Astrometry with SIM PlanetQuest

Precision astrometry at microarcsecond accuracy has application to a wide range of astrophysical problems. This paper is a study of the science questions that can be addressed using an instrument that delivers parallaxes at about 4 microarcsec on targets as faint as V = 20, differential accuracy of 0.6 microarcsec on bright targets, and with flexible scheduling. The science topics are drawn primarily from the Team Key Projects, selected in 2000, for the Space Interferometry Mission PlanetQuest (SIM PlanetQuest). We use the capabilities of this mission to illustrate the importance of the next level of astrometric precision in modern astrophysics. SIM PlanetQuest is currently in the detailed design phase, having completed all of the enabling technologies needed for the flight instrument in 2005. It will be the first space-based long baseline Michelson interferometer designed for precision astrometry. SIM will contribute strongly to many astronomical fields including stellar and galactic astrophysics, planetary systems around nearby stars, and the study of quasar and AGN nuclei. SIM will search for planets with masses as small as an Earth orbiting in the `habitable zone' around the nearest stars using differential astrometry, and could discover many dozen if Earth-like planets are common. It will be the most capable instrument for detecting planets around young stars, thereby providing insights into how planetary systems are born and how they evolve with time. SIM will observe significant numbers of very high- and low-mass stars, providing stellar masses to 1%, the accuracy needed to challenge physical models. Using precision proper motion measurements, SIM will probe the galactic mass distribution and the formation and evolution of the Galactic halo. (abridged)Comment: 54 pages, 28 figures, uses emulateapj. Submitted to PAS

ASTEROSEISMIC DETERMINATION OF OBLIQUITIES OF THE EXOPLANET SYSTEMS KEPLER-50 AND KEPLER-65

Results on the obliquity of exoplanet host stars—the angle between the stellar spin axis and the planetary orbital axis—provide important diagnostic information for theories describing planetary formation. Here we present the first application of asteroseismology to the problem of stellar obliquity determination in systems with transiting planets and Sun-like host stars. We consider two systems observed by the NASA Kepler mission which have multiple transiting small (super-Earth sized) planets: the previously reported Kepler-50 and a new system, Kepler-65, whose planets we validate in this paper. Both stars show rich spectra of solar-like oscillations. From the asteroseismic analysis we find that each host has its rotation axis nearly perpendicular to the line of sight with the sines of the angles constrained at the 1σ level to lie above 0.97 and 0.91, respectively. We use statistical arguments to show that coplanar orbits are favored in both systems, and that the orientations of the planetary orbits and the stellar rotation axis are correlated.United States. National Aeronautics and Space Administration (Kepler Participating Scientist Program Grant NNX12AC76G

Personalized Drug Dosage – Closing the Loop

A brief account is given of various approaches to the individualization of drug dosage, including the use of pharmacodynamic markers, therapeutic monitoring of plasma drug concentrations, genotyping, computer-guided dosage using ‘dashboards’, and automatic closed-loop control of pharmacological action. The potential for linking the real patient to his or her ‘virtual twin’ through the application of physiologically-based pharmacokinetic modeling is also discussed